Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis

MAHDAL, Michal, Lukáš PAZOUREK, Vasileios APOSTOLOPOULOS, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Iva STANICZKOVÁ ZAMBO and Tomáš TOMÁŠ. Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis. CURRENT ONCOLOGY. Basel: MDPI, 2022, vol. 29, No 5, p. 3519-3530. ISSN 1198-0052. Available from: https://dx.doi.org/10.3390/curroncol29050284.

Basic information

• Original name: Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis
• Authors: MAHDAL, Michal (203 Czech Republic, belonging to the institution), Lukáš PAZOUREK (203 Czech Republic, belonging to the institution), Vasileios APOSTOLOPOULOS (203 Czech Republic, belonging to the institution), Dagmar ADÁMKOVÁ KRÁKOROVÁ (203 Czech Republic), Iva STANICZKOVÁ ZAMBO (203 Czech Republic, belonging to the institution) and Tomáš TOMÁŠ (203 Czech Republic, guarantor, belonging to the institution).
• Edition: CURRENT ONCOLOGY, Basel, MDPI, 2022, 1198-0052.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30204 Oncology
• Country of publisher: Switzerland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 2.600
• RIV identification code: RIV/00216224:14110/22:00127136
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3390/curroncol29050284
• UT WoS: 000801930500001
• Keywords in English: bone neoplasm; metastasis; diaphysis of long bones; intercalary endoprosthesis
• Tags: 14110112, 14110123, rivok
• Tags: International impact, Reviewed

Abstract

The purpose of this study was to evaluate the implant survival, functional score and complications of intercalary endoprostheses implanted for metastatic involvement of the femoral and humeral diaphysis. The mean follow-up was 29.8 months. In our group of 25 patients with 27 intercalary endoprostheses (18 femurs, 9 humeri), there were 7 implant-related complications (25.9%), which were more common on the humerus (4 cases, 44.4%) than on the femur (3 cases, 16.7%). Only type II failure—aseptic loosening (5 cases, 18.5%)—and type III failure—structural failure (2 cases, 7.4%)—occurred. There was a significantly higher risk of aseptic loosening of the endoprosthesis in the humerus compared with that in the femur (odds ratio 13.79, 95% confidence interval 1.22–151.05, p = 0.0297). The overall cumulative implant survival was 92% 1 year after surgery and 72% 5 years after surgery. The average MSTS score was 82%. The MSTS score was significantly lower (p = 0.008) in the humerus (75.9%) than in the femur (84.8%). The resection of bone metastases and replacement with intercalary endoprosthesis has excellent immediate functional results with an acceptable level of complications in prognostically favourable patients.